Anti-Mouse CD27 (RM27-3E5) In Vivo Antibody - Low Endotoxin

Functional Assays, Flow Cytometry, ImmunoPrecipitation

Rat IgG1 Kappa

Blue ice

Aggregation level ≤ 5%

CD27 is expressed on T cells, B cells, and NK cells

CD27 is a glycosylated, type I transmembrane protein of the TNFR superfamily that is constitutively expressed on the surface of progenitor and naïve T cells as well as subsets of natural killer (NK) and B cells. CD27 is an immune-checkpoint receptor and ligation with CD70 results in co-stimulatory effects that enhance primary, memory, and recall T cell responses. CD27 signaling has been targeted for the development of viral, autoimmune, and anti-tumor immunotherapies.

RM27-3E5 (rat IgG2a) was raised against recombinant mouse CD27-human IgG1 Fc fusion protein and purified from ascites using protein G columns. RM27-3E5 enhances anti-CD3-stimulated T cell proliferation when immobilized in vitro and augments ovalbumin-specific cytotoxic T lymphocyte (CTL) induction when administered in vivo.

RM27-3E5 is an agonistic antibody and has been found to support the control of both established lung metastases and subcutaneous tumors. An anti-tumor effect was also observed with RM27-3E5 against EG7/CD27(+) and EG7/CD27(−) tumors, with the effect mediated mainly by T cells with a minor contribution by NK cells. RM27-3E5 exerts its potent anti-tumor effect by inducing a tumor-specific CTL response. RM27-3E5 has potential utility as a non-depleting agonistic anti-CD27 mAb to enhance anti-tumor immunity

<1.0 EU/mg as determined by the LAL method

This monoclonal antibody was purified using Protein G

Mouse CD27-human IgG1 Fc fusion protein

ICH3001-100ml; ICH3002-100ml; ICH3003-100ml